Dividends4Life: Stock Analysis: Johnson & Johnson (JNJ)

Stock Analysis: Johnson & Johnson (JNJ)

Posted by D4L | Thursday, May 27, 2010 | | 0 comments »

Johnson & Johnson engages in the manufacture and sale of various products in the health care field worldwide.

There is no perfect dividend growth stock, but JNJ comes close. The company enjoys a diverse revenue base, an excellent research pipeline, a pristine balance sheet and exceptional free cash-flows to cover it dividend. This diversity and strength will help the company overcome near-term results from patent losses on Risperdal and Topamax. I will continue to add to my position as my allocation allows and when JNJ is trading below my buy price of $70.24.

Source: Dividends Value

Related Articles:

Click here to have future posts delivered to you for free!



Post a Comment

Note: Only a member of this blog may post a comment.

Dividend Growth Stocks News


Popular Posts Last 30 Days